Cancer after intense and prolonged antiplatelet therapies – fact or fiction?

Raffaele De Caterina

doi:10.1160/TH15-11-0842

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2015; 114(06): 1100-1103
DOI: 10.1160/TH15-11-0842

Current Controversies

Schattauer GmbH

Cancer after intense and prolonged antiplatelet therapies – fact or fiction?

Raffaele De Caterina

¹University Cardiology Division, G. d’Annunzio University – Chieti, Italy

References
1 Serebruany V. et al. Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges. Thromb Haemost 2015; 114: 1104-1112.
2 Baigent C, Blackwell L, Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
3 Rothwell PM. et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41.
4 Rothwell PM. et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379: 1602-1612.
5 Mills EJ. et al. Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Am J Med 2012; 125: 560-577.
6 The Medical Research Council’S General Practice Research Framework. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233-241.
7 Patrignani P. et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. J Thromb Haemost 2014; 12: 1320-1330.
8 Guillem-Llobat P. et al. Platelets, cyclooxygenases, and colon cancer. Semin Oncol 2014; 41: 385-396.
9 Dovizio M. et al. Role of platelets in inflammation and cancer: novel therapeutic strategies. Basic Clin Pharmacol Toxicol 2014; 114: 118-127.
10 Patrono C. The multifaceted clinical readouts of platelet inhibition by low-dose aspirin. J Am Coll Cardiol 2015; 66: 74-85.
11 Halvorsen S. et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am Coll Cardiol 2014; 64: 319-327.
12 A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
13 Wang Y. et al. Platelet P2Y12 is involved in murine pulmonary metastasis. PLoS One 2013; 08: e80780.
14 Adamski P. et al. Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thromb Hae-most 2014; 112: 224-242.
15 Trenk D. et al. High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials. Thromb Haemost 2013; 109: 834-845.
16 Aradi D. et al. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Thromb Hae-most 2013; 109: 93-101.
17 Mauri L. et al. Twelve or 30 months of dual anti-platelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-2166.
18 Wiviott SD. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
19 Roe MT. et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367: 1297-1309.
20 Bonaca MP. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-1800.
21 Wallentin L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
22 Tricoci P. et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20-33.
23 Morrow DA. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-1413.
24 Santilli F. et al. Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefit profile to person-alised treatment. Thromb Haemost 2015; 114: 876-882.
25 De Caterina R. et al. Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. Eur Heart J 2010; 31: 2133-2140.
26 Connolly SJ. et al. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011; 155: 579-586.
27 Connolly SJ. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
28 Giugliano RP. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
29 Renda G, di Nicola M, De Caterina R. Net clinical benefit of non-vitamin K antagonist oral anticoagulants versus warfarin in phase III atrial fibrillation trials. Am J Med 2015; 128: 1007-1014e2.
30 U.S. Food and Drug Administration [Internet]. Plavix (clopidogrel): Drug safety communication. Long-term treatment does not change risk of death. FDA; 2015. November 6 [cited on 2015 November 7]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm471531.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery